Inhibition of protein synthesis by streptomycin was tested in extracts from a strain of Escherichia coli sensitive to streptomycin. Three kinds of messenger ribonucleic acid (RNA) were employed: endogenous cellular RNA, extracted cellular RNA, and phage R17 RNA. Protein synthesis directed by extracted cellular RNA was inhibited three-to fourfold more than protein synthesis directed by endogenous RNA. With R17 RNA as messenger, nearly total inhibition of protein synthesis at initiation was again observed. The greater inhibition of function of extracted RNA, which must initiate new polypeptide chains in vitro, is in accord with the observation that in whole cells streptomycin blocks ribosomes at an early stage in protein synthesis. When streptomycin was added at successively later times during protein synthesis, the subsequent inhibition was progressively less. This was observed with either extracted cellular RNA or phage R17 RNA. A model is presented that can explain the less drastic inhibition by streptomycin of messenger RNA that is already functioning on ribosomes.
Streptomycin provokes the accumulation in treated cells of "str-monosomes" (6, 7) . These are ribosomes blocked irreversibly, each on a chain of messenger ribonucleic acid (mRNA), at an early stage of protein synthesis. The effects of streptomycin in crude cell extracts are generally in accord with the selective blockage of the initiation of protein synthesis. For example, protein synthesis directed by phage ribonucleic acid is severely inhibited (1) at initiation (6) . As expected, protein synthesis directed by endogenous mRNA, or by artificial polymers like polyuridylic acid that bypass the natural initiation mechanism, is also inhibited, but not so extensively (2) . However, the degree to which streptomycin inhibits protein synthesis in extracts is influenced by many variables, for example, the ionic composition of the medium. In this report we describe a difference in the susceptibility to streptomycin action between (i) mRNA already on ribosomes when cells are extracted and (ii) the same mRNA or R17 phage RNA after it was extracted and added to ribosomes.
MATERIALS AND METHODS
The growth of the streptomycin-sensitive Escherichia coli strain AB301, preparation of extracts by l Present address: Department of Hematology, University College Hospital, Ibadan, Nigeria. alumina grinding, and assays of protein synthesis were all carried out by standard procedures (3, 6, 12) . For assays of endogenous mRNA activity, nonpreincubated extracts treated with deoxyribonuclease were used (15) . To study the function of added mRNA, polyuridylic acid (12), R17 phage RNA (3), or total extracted cellular RNA (16) was added to extracts that were already preincubated as described (3, 12) .
In allcases, reaction mixtures were incubated for 30 min at 36 C, then precipitated with 5% trichloracetic acid, boiled for 20 min at 90 C, and then plated and washed on glass fiber filters with three 3-ml portions of the acid. Counts per minute were measured in a gas-flow counter fitted with a thin window, with an efficiency of about 30%. '4C-alanine ( and then added back to ribosomes to direct amino acid incorporation, its susceptibility to inhibition by streptomycin was sharply increased. In contrast to the results with endogenous mRNA in an extract, amino acid incorporation was almost 0 completely prevented by added drug, and the inhibition was only partially alleviated at higher levels of Mg2+ (Fig. 1) . 0o Qualitatively similar results were obtained 15 i when a single, pure mRNA, that from phage R17, 15 20 was used (Table 1) . In this case, incorporation. was inhibited almost completely when streptomycin was added at the start of the incorporation gmino acid in-reaction. Inhibition was severe even when the )genous or ex-drug was added some minutes after incorporation was followed began. This may be because initiation of protein or in a pre-synthesis is usually rate-limiting in cell-free exracted E. coli tracts (5) a Protein synthesis was followed in a reaction mixture to which no streptomycin was added, and in replicate mixtures to which 3 Ag of streptomycin per ml was added at 0, 7, or 11 min. At each sampling time, control samples to which no R17 RNA had been added were processed. The reaction mixtures contained 5,pc of '4C-alanine, R17 RNA, and additives per ml according to reference 3; 3 pg of streptomycin were added to some samples for the indicated times. Counts per minute of amino acid incorporated were measured on 50-pliter triplicate portions, with a precision of -3%e. To correct for the residual incorporation due to endogenous mRNA in the preincubated extract, each sample was paired with controls identical except that they contained no added R17 phage RNA. The low levels of incorporation observed in the controls (20 to 100 counts/min), depending on the sampling time, were then subtracted from the corresponding experimental samples to give the reported values.
The findings reported here, that exogenous mRNA is more inhibited by streptomycin than is endogenous mRNA, are in agreement with the in vivo findings of blockage at initiation of protein synthesis. However, further complexities are observed in vitro.
First, as is indicated in Table 1 , when in vitro protein synthesis is directed by R17 phage RNA, streptomycin can inhibit incorporation severely even several minutes after the reaction begins. Whereas most ribosomes at that time may still be blocked at initiation sequences (3), at least some must have progressed beyond initiation. Second, with endogenous mRNA as well as R17 phage RNA, when the drug was added later, streptomycin inhibition of remaining incorporation was less.
One explanation for these additional observations can be based on the mRNA breakdown during the incubations. This could generate artificial fragments on which abnormal, streptomycin-resistant initiation can take place.
A more attractive possibility would rationalize both the decrease in inhibition with incubation time and the greater inhibition of exogenous compared to endogenous mRNA. It is based on the difference between the way that ribosomes add to mRNA in the cell and in extracts. This distinction has gradually become clear. In whole cells, ribosomes add to mRNA as the mRNA chain is being polymerized (9, 11, 14) , very possibly only while the mRNA chain is being formed (9) . The following model could thus be visualized. During in vivo protein synthesis, a packet of ribosomes moves along an mRNA chain that is relatively uniformly extended, whereas in extracts, each ribosome must bind to a more or less complete mRNA chain. The isolated messenger in vitro, bearing no ribosome, is much more coiled than the same messenger in vivo. Thus, the ribosomemRNA complex formed in vitro can be more accessible to streptomycin. As the ribosome continues to move in vitro and the mRNA begins to unfold, the ribosome interaction with the mRNA becomes more similar to the usual relationship of ribosome and mRNA in vivo, and the susceptibility to streptomycin action decreases.
Recently, Modolell and Davis (10) have claimed that streptomycin inhibits protein synthesis at the level of peptide-chain elongation, rather than initiation, because R17 RNA-directed amino acid incorporation in vitro shuts down immediately upon addition of the drug. The model presented above accounts for their data as well as ours. Moreover, it is clear from the evidence detailed elsewhere (7) that, in the intact cell, as with endogenous mRNA in vitro, chain elongation continues for some time after adding streptomycin until all ribosomes recycle and are blocked at an early step in protein synthesis.
